{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:54:46Z","timestamp":1767138886494,"version":"build-2238731810"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"DOI":"10.1007\/s00108-022-01342-8","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T07:02:47Z","timestamp":1652079767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Konservative Therapie der peripheren arteriellen Verschlusskrankheit","Conservative treatment of peripheral arterial disease"],"prefix":"10.1007","author":[{"given":"Christine","family":"Espinola-Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Wei\u00dfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"1342_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab390","author":"V Aboyans","year":"2020","unstructured":"Aboyans\u00a0V, Bauersachs\u00a0R, Mazzolai\u00a0L et\u00a0al (2020) Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a\u00a0consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab390","journal-title":"Eur Heart J"},{"key":"1342_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx095","author":"V Aboyans","year":"2017","unstructured":"Aboyans\u00a0V, Ricco\u00a0JB, Bartelink\u00a0MEL et\u00a0al (2017) ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095","journal-title":"Eur Heart J"},{"key":"1342_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jama.2012.216237","volume":"309","author":"AA Ahimastos","year":"2013","unstructured":"Ahimastos\u00a0AA, Walker\u00a0PJ, Askew\u00a0C et\u00a0al (2013) Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a\u00a0randomized controlled trial. JAMA 309:453\u2013460","journal-title":"JAMA"},{"key":"1342_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2017","unstructured":"Anand\u00a0SS, Bosch\u00a0J, Eikelboom\u00a0JW et al (2017) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391:219\u2013229","journal-title":"Lancet"},{"key":"1342_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","volume":"137","author":"S Arya","year":"2018","unstructured":"Arya\u00a0S, Khakharia\u00a0A, Binney\u00a0ZO et\u00a0al (2018) Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 137:1435\u20131446","journal-title":"Circulation"},{"key":"1342_CR6","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca\u00a0MP, Bauersachs\u00a0RM, Anand\u00a0SS et\u00a0al (2020) Rivaroxaban in peripheral artery disease after revascularization. N\u00a0Engl J Med 382:1994\u20132004","journal-title":"N Engl J Med"},{"key":"1342_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca\u00a0MP, Nault\u00a0P, Giugliano\u00a0RP et al (2018) Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 137:338\u2013350","journal-title":"Circulation"},{"issue":"20","key":"1342_CR8","first-page":"1329","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(20):1329\u20131339","journal-title":"Lancet"},{"key":"1342_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486","author":"F Cosentino","year":"2019","unstructured":"Cosentino\u00a0F, Grant\u00a0PJ, Aboyans\u00a0V et al (2019) ESC\/EASD Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"key":"1342_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.7861\/clinmed.2020-0359","volume":"20","author":"W Ekezie","year":"2020","unstructured":"Ekezie\u00a0W, Murray\u00a0RL, Agrawal\u00a0S et al (2020) Quality of smoking cessation advice in guidelines of tabacco-related diseases: An update and systematic review. Clin Med 20:551\u2013559","journal-title":"Clin Med"},{"key":"1342_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1724-4922","volume":"42","author":"C Espinola-Klein","year":"2022","unstructured":"Espinola-Klein\u00a0C (2022) When and how to combine antiplatelet and anticoagulant drugs? Hamostaseologie 42:73\u201379","journal-title":"Hamostaseologie"},{"key":"1342_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jacc.2018.06.041","volume":"72","author":"CN Hess","year":"2018","unstructured":"Hess\u00a0CN, Rogers\u00a0RK, Wang\u00a0TY et al (2018) Major adverse limb events and 1\u2011year outcomes after peripheral artery revascularization. J\u00a0Am Coll Cardiol 72:999\u20131011","journal-title":"J Am Coll Cardiol"},{"key":"1342_CR13","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.3390\/jcm10215033","volume":"10","author":"K Keller","year":"2021","unstructured":"Keller\u00a0K, Schmitt\u00a0VH, Vosseler\u00a0M et al (2021) Diabetes Mellitus and its impact on patient-profile and in-hospital outcomes in peripheral artery disease. J\u00a0Clin Med 10:5033. https:\/\/doi.org\/10.3390\/jcm10215033","journal-title":"J Clin Med"},{"issue":"Suppl 95","key":"1342_CR14","first-page":"11","volume":"45","author":"H Lawall","year":"2016","unstructured":"Lawall\u00a0H, Huppert\u00a0P, R\u00fcmenapf\u00a0G et al (2016) S3-Leitlinien zurDiagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Vasa 45(Suppl 95):11\u201382","journal-title":"Vasa"},{"key":"1342_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejvs.2016.12.035","volume":"53","author":"H Lawall","year":"2017","unstructured":"Lawall\u00a0H, Pokrovsky\u00a0A, Checinski\u00a0P et\u00a0al (2017) Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease fontaine stage IV: results of a\u00a0placebo controlled randomised multicentre trial (ESPECIAL). Eur J Vasc Endovasc Surg 53:559\u2013566","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"41","key":"1342_CR16","first-page":"111","volume":"2020","author":"F Mach","year":"2019","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2019) ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 2020(41):111\u2013188","journal-title":"Eur Heart J"},{"key":"1342_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","volume":"268","author":"W M\u00e4rz","year":"2018","unstructured":"M\u00e4rz\u00a0W, Dippel\u00a0FW, Theobald\u00a0K et al (2018) Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis 268:99\u2013107","journal-title":"Atherosclerosis"},{"key":"1342_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","volume":"108","author":"ER Mohler","year":"2003","unstructured":"Mohler\u00a0ER, Hiatt\u00a0WR, Creager\u00a0MA et\u00a0al (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108:1481\u20131486","journal-title":"Circulation"},{"key":"1342_CR19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1055\/s-0040-1709711","volume":"120","author":"D Pastori","year":"2020","unstructured":"Pastori\u00a0D, Farcomeni\u00a0A, Milanese\u00a0A et al (2020) Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 120:866\u2013875","journal-title":"Thromb Haemost"},{"key":"1342_CR20","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"Song\u00a0P, Rudan\u00a0D, Zhu\u00a0Y et\u00a0al (2019) Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 7:e1020\u2013e1030","journal-title":"Lancet Glob Health"},{"key":"1342_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma\u00a0S, Mazer\u00a0CD, Al-Omran\u00a0M et al (2018) Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137:405\u2013407","journal-title":"Circulation"},{"key":"1342_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab245","author":"J Willett","year":"2021","unstructured":"Willett\u00a0J, Achenbach\u00a0S, Pinto\u00a0FJ et\u00a0al (2021) The tobacco endgame\u2014Eradicating a\u00a0worsening epidemic. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab245","journal-title":"Eur Heart J"}],"updated-by":[{"DOI":"10.1007\/s00108-022-01356-2","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000}}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01342-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01342-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01342-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T07:03:28Z","timestamp":1652079808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01342-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":22,"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01342-8","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"25 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Espinola-Klein: Vortragst\u00e4tigkeit, Beratert\u00e4tigkeit, Unterst\u00fctzung von Veranstaltungen durch Amarin Germany, Amgen, Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Cordis, Daiichi Sankyo, Leo, MSD Sharp & Dohme, Novartis, Pfizer, Sanofi-Aventis. G.\u00a0Wei\u00dfer: Vortragst\u00e4tigkeit Bayer Health Care, Bristol-Myers Squibb, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}